// App-Quantinova.ai

PO2629 : Effect of Ertugliflozin on Initial eGFR Decline and Chronic Slope: Analyses from the VERTIS CV Trial

Researchers

Presenter

  • Cherney David

Principal Investigators

  • Charbonnel Bernard

  • Cosentino Francesco

  • Pratley RichardE

  • Dagogo-Jack Samuel

  • Shih WeichungJ

  • Mcguire DarrenK

  • Frederich Robert

  • Maldonado Mario

  • Liu Jie

  • Pong Annpey

  • Liu Chih-Chin

  • Cannon ChristopherP

Medical Centers

  • Anh Dung, University of Toronto, Toronto, Ontario, Canada

  • Universite de Nantes Nantes Pays de la Loire France

  • Karolinska Institutet, Karolinska University Hospital and SweBCG, Stockholm, Sweden

  • AdventHealth Translational Research Institute Orlando Florida United States

  • University of Tennessee Health Science Center, Memphis, Tennessee, United States

  • Rutgers School of Public Health, Piscataway, NJ, United States,

  • UT Southwestern Medical Center, Dallas, Texas, United States

  • Pfizer, Inc., Collegeville, Pennsylvania, United States

  • LA-SER Limited, London, United Kingdom

  • Merck & Co. Inc. Kenilworth New Jersey United States

  • Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States

Locations

  • Canada

  • France

  • Sweden

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Coronary Artery Disease

  • Type 2 diabetes mellitus

Biomarkers

  • N/A

Drug/Treatment

  • Ertugliflozin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved